Cypress Asset Management Inc Gilead Sciences, Inc. Transaction History

Cypress Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$60.54 - $79.0 $169,512 - $221,200	-2,800 Closed	0 $0
Q3 2018 Oct 19, 2018	SELL	$71.28 - $78.92 $17,820 - $19,730	-250 Reduced 8.2%	2,800 $216,000
Q2 2018 Jul 27, 2018	SELL	$64.88 - $75.68 $945,950 - $1.1 Million	-14,580 Reduced 82.7%	3,050 $216,000
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $80,488 - $98,124	-1,105 Reduced 5.9%	17,630 $1.33 Million
Q4 2017 Jan 31, 2018	SELL	$71.15 - $83.52 $170,048 - $199,612	-2,390 Reduced 11.31%	18,735 $1.34 Million
Q3 2017 Nov 08, 2017	BUY	$72.11 - $85.47 $1.52 Million - $1.81 Million	21,125	21,125 $1.71 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Cypress Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cypress Asset Management Inc with notifications on news.